Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

The impact of recurrence timing and tumor burden score on overall survival among patients undergoing repeat hepatectomy for colorectal liver metastases.

The impact of recurrence timing and tumor burden score on overall survival among patients undergoing repeat hepatectomy for colorectal liver metastases. Journal of surgical oncology Endo, Y., Rueda, B. O., Woldesenbet, S., Munir, M. M., Lima, H. A., Katayama, E. S., Shaikh, C. F., Guglielmi, A., Ruzzenente, A., Aldrighetti, L., Alexandrescu, S., Kitago, M., Poultsides, G., Sasaki, K., Aucejo, F., Pawlik, T. M. 2023

Abstract

Approximately 15% of patients experience a resectable intrahepatic recurrence after an index curative-intent hepatectomy for colorectal liver metastases (CRLM). We sought to investigate the impact of recurrence timing and tumor burden score (TBS) at the time of recurrence on overall survival among patients undergoing repeat hepatectomy.Patients with CRLM who experienced recurrent intrahepatic disease after initial hepatectomy between 2000 and 2020 were identified from an international multi-institutional database. The impact of time-TBS, defined as TBS divided by the time interval of recurrence, was assessed relative to overall survival.Among 220 patients, the median age was 60.9 years (interquartile range [IQR]: 53.0-69.0), and 144 (65.5%) patients were male. Most patients experienced multiple recurrences (n?=?120, 54.5%) within 12 months after the initial hepatectomy (n?=?139, 63.2%). The median tumor size of the recurrent CRLM was 2.2?cm (IQR: 1.5-3.0?cm) with a median TBS of 3.5 (2.3-4.9) at the time of recurrence. Overall, 121 (55.0%) patients underwent repeat hepatectomy, whereas 99 (45.0%) individuals were treated with systemic chemotherapy or other nonsurgical treatments; repeat hepatectomy was associated with better postrecurrence survival (PRS) (p?

View details for DOI 10.1002/jso.27314

View details for PubMedID 37195231